Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 TrialBernstein JA, Riedl MA, Lumry WR, Audhya PK, Smith MD, Yea CM
AAAAI 2023
A Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy VolunteersSmith MD, Iverson M, Hansen E, Audhya PK, Yea CM
AAAAI 2023
Patient Perspectives On Early Use Of On-demand Treatment For Hereditary Angioedema (HAE) Attacks to Reduce Severity and DurationRadojicic C, Manning M, Guilarte M, Heckmann M, van Kooten S, Danese S, Goga L
AAAAI 2023
Factor XII contributes to VEGF-induced retinal edema and neuroretinal responses in miceClermont AC, Murugesan N, Ustunkaya T, Aiello LP, Feener EP
ARVO 2023
Reporting of Adverse Drug Reactions with Parenteral Drugs for the On-Demand Treatment of Hereditary Angioedema Attacks – Analysis of the FAERS Database 2009 to 2022Tachdjian R, Savi S, Fridman M, Frade J, Audhya PK, Fasehun M
AAAAI 2023
Targeted Literature Review to Assess the Studies Supporting Short-term Prophylactic Treatment Options for the Preprocedural Prevention of Attacks in Patients With Hereditary AngioedemaRiedl MA, Bernstein JA, Lumry WR, Audhya PK, Smith MD, Yea CM
WSAAI 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Sebetralstat in Healthy Japanese and White Adults: Results From a Phase 1, Randomized, Double-Blind, Placebo-Controlled TrialIverson M, Jhee S, Hansen E, Duckworth EJ , Hampton SL, Yoon E
WSAAI 2023
Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary AngioedemaAygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD
WSAAI 2023
